Aurobindo Pharma Ltd


BSE: 524804 | NSE: AUROPHARMA | ISIN: INE406A01037 
Market Cap: [Rs.Cr.] 5,598 | Face Value: [Rs.] 1
Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

 Discuss this stock

Board Meet

30-May-13 
Aurobindo Pharma Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 30, 2013, inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2013. Further, the Board will also consider recommendation of Final Dividend, if any, for the year 2012-13. 
07-Feb-13 
Aurobindo Pharma Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 07, 2013, inter alia, to consider the Un-Audited Financial Results of the Company for the quarter ended December 31, 2012 (Q3). With reference to the earlier announcement dated January 21, 2013, regarding the Board Meeting of the Company will be held on February 07, 2013, inter alia, to consider the Un-Audited Financial Results of the Company for the quarter ended December 31, 2012 (Q3), Aurobindo Pharma Ltd has now informed BSE that at the said Board Meeting to be held on February 07, 2013, the Board will also consider the proposal of payment of Interim Dividend for the year 2012-13. (As per BSE Announcement Dated on 04.02.2013) Aurobindo Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 07, 2013, inter alia, has approved an interim dividend @100% i.e. Re.1/- (Rupees One Only) per equity share of Re. 1 (Rupees One only) for the year 2012-13. (As per BSE Announcement Dated on 07.02.2013) 
09-Nov-12 
Quarterly Results Aurobindo Pharma Ltd has informed BSE that Mr. Ravindra Y. Shenoy, Joint Managing Director of the Company has tendered his resignation due to his unavoidable personal family reasons. The Board of Directors of the Company at their meeting held on November 09, 2012 have accepted his resignation and consented to relieve Mr. Shenoy of his duties and responsibilities vested by the Board as Director & Joint Managing Director of the Company, with effect from the close of working hours on November 09, 2012. (As per BSE Announcement Dated on 09.11.2012)  
25-Aug-12 
Aurobindo Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 25, 2012, have approved the proposal of appointment of Mr. P. V. Ramprasad Reddy as Executive Chairman of Aurobindo Pharma USA, Inc., the wholly owned subsidiary of the Company w.e.f. December 01, 2012. The said proposal is subject to further approval of the shareholders of the Company. Accordingly, an Extra Ordinary General Meeting of the Company is being convened on September 27, 2012. Consequent to his proposed appointment in the Company's US subsidiary, the Board has also approved Mr. Ramprasad Reddy relinquishing the executive responsibilities as Wholetime Director of the Company and his continuation as a Non-Executive Director of the Company not liable to retire by rotation with effect from December 01, 2012. 
07-Aug-12 
Aurobindo Pharma Ltd has informed BSE that a Meeting of the Board of Directors of the Company will be held on August 07, 2012, inter alia, to consider the Un-Audited Financial Results of the Company for the quarter ended June 30, 2012 (Q1). 

AGM

07-Aug-12
Aurobindo Pharma Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from August 01, 2012 to August 07, 2012 (both days inclusive) for the purpose of Payment of Dividend & 25th Annual General Meeting (AGM) of the Company to be held on August 07, 2012. Aurobindo Pharma Ltd has informed BSE that the 25th Annual General Meeting (AGM) of the Company will be held on August 07, 2012. (AsPer BSE ANnouncement Website Dated on 18/07/2012) Aurobindo Pharma Ltd has informed BSE regarding details of Voting Results at the 25th Annual General Meeting (AGM) of the Company held on August 07, 2012, under Clause 35A. (As Per BSE Announcement Website Dated on 08/08/2012) Aurobindo Pharma Limited has informed the Exchange that Dr.P.L.Sanjeev Reddy a Non-Executive and Independent Director ceased to be Director of the Company consequent to his non seeking reappointment at the Annual General Meeting of the Company held on August 07,2012. (As Per NSE Bulletin Dated on 10.08.2012) Aurobindo Pharma Ltd has informed BSE that Dr. P. L. Sanjeev Reddy a Non-Executive and Independent Director ceased to be Director of the Company consequent to his non seeking reappointment at the Annual General Meeting of the Company held on August 07, 2012. (As Per BSE Announcement Website Dated on 11/08/2012) 
29-Jul-11
Aurobindo Pharma Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from July 22, 2011 to July 29, 2011 (both days inclusive) for the purpose of Payment of Final Dividend & 24th Annual General Meeting (AGM) of the Company to be held on July 29, 2011. Aurobindo Pharma Ltd has informed BSE that the members at the 24th Annual General Meeting (AGM) of the Company held on July 29, 2011, have unanimously approved the following: 1. Audited Annual Accounts of the Company for the year ended March 31, 2011. 2. Final Dividend @ 100% i.e., Re. 1/- per share of Re. 1/- each (Interim Dividend @ 100% i.e., Rs. 5/- per share of Rs. 5/- each, which was already paid) for the year 2010-2011. 3. Re-appointment of Mr. K. Ragunathan, Dr. M. Sivakumaran and Mr. M. Madan Mohan Reddy as Directors of the Company. 4. Re-appointment of S. R. Batliboi & Associates., as Statutory Auditors of the Company. 5. Re-appointment of Mr. P. V. Ramprasad Reddy as Executive Chairman and Mr. K. Nithyananda Reddy as Managing Director of the Company. 6. Revision of Remuneration payable to Ms. Kirthi Reddy, Head - Unit-IV, a relative of Directors. 7. Enhancement of sitting fees payable to Directors subject to approval of Central Government. The final dividend declared at the meeting will be paid to the shareholders on August 05, 2011. (As Per BSE annoncement Website Dated on 30/07/2011) 
23-Sep-10
AGM 23/09/2010 Aurobindo Pharma Ltd has informed BSE that the members at the Annual General Meeting (AGM) of the Company held on September 23, 2010, inter alia, have accorded to the following: 1. Audited Annual Accounts of the Company for the year ended March 31, 2010. 2. Final Dividend @ 40% i.e., Rs.2/- per share (Interim Dividend @ 60% i.e. Rs. 3/- per share already paid) for the year 2009-2010. 3. Re- appointment of Dr. K Ramachandran, Dr. P L Sanjeev Reddy and Mr. P Sarath Chandra Reddy as Directors of the Company. 4. Re-appointment of S R Batliboi & Associates., as Statutory Auditors of the Company. (As Per BSE Announcement Website dated on 23.09.2010) 
23-Dec-09
To convene the 22nd Annual General Meeting of the Company on December 23, 2009. Aurobindo Pharma Ltd has informed BSE that the members at the Annual General Meeting (AGM) of the Company held on December 23, 2009, inter alia, have approved the following: 1. Audited Annual Accounts of the Company for the year 2008-2009. 2. Final Dividend @ 30% i.e., Rs. 1.50 per share (Interim Dividend @ 60% i.e. Rs. 3.00 per share already paid) for the year 2008-2009. 3. Re-appointment of Dr. M. Sivakumaran, Mr. M. Madan Mohan Reddy and Mr. M. Sitarama Murthy as Directors of the Company. 4. Re-appointment of S. R. Batliboi & Associates, as Statutory Auditors of the Company. 5. Revision of remuneration of Mr. P. V. Ramaprasad Reddy, Chairman, Mr. K. Nithyananda Reddy, Managing Director and Dr. M. Sivakumaran, Wholetime Director. 6. Re-appointment of Dr. M. Sivakumaran and Mr. M. Madan Mohan Reddy as Wholetime Directors of the Company. 7. Appointment of Ms. K. Kirthi Reddy and Mr. Vishnu M. Sriram under section 314 of the Companies Act, 1956. 8. Appointment of Dr. D. Rajagopala Reddy as a Director of the Company. (As Per BSE Announcement Dated on 23/12/2009) 
20-Aug-08
AGM 20/08/2008 Aurobindo Pharma Ltd has informed BSE that the members at the Annual General Meeting (AGM) of the Company held on August 20, 2008, have approved the following: 1. Audited Annual Accounts of the Company for the year 2007-2008. 2. Dividend @ 65% i.e., Rs 3.25 per share for the year 2007-2008. 3. Appointment of S R Batliboi & Associates., as Statutory Auditors of the Company. 4. Re-appointment of Dr. S Bimal Singh and Dr. K Ramachandran as Directors of the Company. 5. Appointment of Mr. K Ragunathan as a Director of the Company. (As per BSE Announcement dated on 22/08/2008) 

EGM

27-Sep-12
Aurobindo Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 25, 2012, have approved the proposal of appointment of Mr. P. V. Ramprasad Reddy as Executive Chairman of Aurobindo Pharma USA, Inc., the wholly owned subsidiary of the Company w.e.f. December 01, 2012. The said proposal is subject to further approval of the shareholders of the Company. Accordingly, an Extra Ordinary General Meeting of the Company is being convened on September 27, 2012. Consequent to his proposed appointment in the Company's US subsidiary, the Board has also approved Mr. Ramprasad Reddy relinquishing the executive responsibilities as Wholetime Director of the Company and his continuation as a Non-Executive Director of the Company not liable to retire by rotation with effect from December 01, 2012. Bhageria Dye Chem Ltd has informed BSE that the 23rd Annual General Meeting (AGM) of the Company was held on September 01, 2012. (As per BSE Announcement Dated on 03.09.2012) Aurobindo Pharma Ltd has informed BSE regarding the details of Voting results at the Extra Ordinary General Meeting (EGM) of the Company held on September 27, 2012, under Clause 35A. (As per BSE Announcement Dated on 28.09.2012)  
23-Dec-10
Aurobindo Pharma Ltd has informed BSE that an Extra Ordinary General Meeting (EGM) of the members of the Company will be held on December 23, 2010, inter alia, to Sub-division of 13,20,00,000 Equity Shares of the face value of Rs. 5/- each in the Authorised Share Capital of the Company into 66,00,00,000 Equity Shares of the face value of Rs. 1/- each. Further to resolve that the existing Clause V of the Memorandum of Association of the Company relating to share capital be altered by deleting the same and substituting in place thereof the following new Clause V. 'V. a) The Authorised Share Capital of the Company is Rs. 76,00,00,000/- (Rupees Seventy Six Crores only) divided into 66,00,00,000 (Sixty Six Crores only) Equity Shares of Re.1/- (Rupee One only) each and 10,00,000 (Ten Lakhs only) Preference Shares of Rs. 100/- (Rupees One Hundred only) each. b) The Company has power from time to time increase in Capital as Equity or preferred Shares and to attach to any class or classes of such Shares, preferences, rights, privileges or priorities in payment of dividends, or distribution of assets, or otherwise over and other shares and to subject the same to any restrictions, limitations or conditions and to vary the regulations of the Company, as to a portion the right to participate in profits in any manner subject to the prior consent of the Government of India or the order of the court, if the same will be necessary being obtained before doing so. Further to resolve that the existing Article 3 of the Articles of Association of the Company relating to share capital be altered by deleting the same and substituting in place thereof the following new Article 3. '3. The Authorised Share Capital of the Company is Rs. 76,00,00,000/- (Rupees Seventy Six Crores only) divided into 66,00,00,000 (Sixty Six Crores only) Equity Shares of Re. 1/- (Rupee One only) each and 10,00,000 (Ten Lakhs only) Preference Shares of Rs. 100/- (Rupees One Hundred only) each and the same may be increased or reduced in accordance with the Companies Act, 1956 and the Memorandum of Association as and when thought fit by the Board of Directors.' Aurobindo Pharma Ltd has informed BSE that the shareholders at the Extraordinary General Meeting (EGM) of the Company held on December 23, 2010, have approved the sub-division of one equity share of the face value of Rs. 5/-each in the Company into five equity shares of the face value of Rs. 1/- each. Aurobindo Pharma Ltd has submitted to BSE a copy of extract of the minutes of the Extra Ordinary General Meeting (EGM) of the Company held on December 23, 2010. (As Per BSE Announcement Website Dated on 23/12/2010) 
20-Jan-10
Aurobindo Pharma Ltd has informed BSE that by an order made on December 09, 2009, the Hon'ble High Court of Judicature of Andhra Pradesh at Hyderabad has directed that a Meeting of the Equity Shareholders of the Applicant Company i.e., Aurobindo Pharma Ltd., be convened and held on January 20, 2010, for the purpose of considering and if thought fit approving, with or without modification(s), the Scheme of Amalgamation proposed to be made between Trident Life Sciences Ltd. and Aurobindo Pharma Ltd. and their respective shareholders. Aurobindo Pharma Ltd has informed BSE that the Shareholders of the Company at their meeting held on January 20, 2010, as per the directions of the Hon'ble High Court of Andhra Pradesh at Hyderabad, have approved the Scheme of Amalgamation between Trident Life Sciences Ltd. (a wholly owned subsidiary of Aurobindo Pharma Ltd.) and Aurobindo Pharma Ltd and their respective Shareholders. (As Per BSE Announcement Website dated on 21.01.2010) 
21-May-09
Aurobindo Pharma Ltd has informed the Exchange that by an order made on April 18, 2009 in the Company Application, the Hon'ble High Court of Judicature of Andhra Pradesh at Hyderabad has directed that a Meeting of the Equity Shareholders of the Applicant Company i.e., Aurobindo Pharma Limited, be convened and held on May 21, 2009 for the purpose of considering and if thought fit approving, with or without modification(s), the arrangements embodied in the Scheme of Arrangement proposed to be made between Aurobindo Pharma Limited and its Shareholders. Aurobindo Pharma Ltd has informed BSE that the Shareholders of the Company at its meeting held on May 21, 2009, as per the directions of the Hon'ble High Court of Andhra Pradesh at Hyderabad, have approved the Scheme of Arrangement between the Company and its Shareholders by requisite majority. The Shareholders have also approved the resolution for the reduction of capital in the form of utilization of Capital Redemption Reserve Account as the proposed Scheme involves Utilization of the Capital Redemption Reserve Account and creation of Reconstruction Reserve Account. (As Per BSE Announcement Website dated on 22.05.2009) 
20-Feb-07
Aurobindo Pharma Ltd has informed BSE that pursuant to the order made by the High Court of Judicature of Andhra Pradesh, at Hyderabad, a meeting of the Equity Shareholders of the Company will be held on February 20, 2007, for the purpose of considering, and if thought fit, approving with or without modification(s), the arrangement embodied in the Scheme of Arrangement proposed to be made between the Company and APL Life Sciences Ltd and Senor Organics Pvt Ltd 

Peer Comparison

Company Market Cap
(Rs. in Cr.)
P/E (TTM)
(x)
P/BV (TTM)
(x)
EV/EBIDTA
(x)
ROE
(%)
ROCE
(%)
D/E
(x)
Sun Pharma.Inds. 99,966.47 69.45 12.33 27.45 26.1 27.0 0.01
Dr Reddy's Labs 35,282.65 27.88 4.63 18.79 14.3 16.6 0.25
Cipla 34,095.15 22.27 4.52 14.11 15.9 19.8 0.03
Ranbaxy Labs. 19,947.05 0.00 10.38 72.87 0.0 0.0 2.38
Wockhardt 19,705.77 117.38 163.78 12.82 237.0 30.3 2.09
Cadila Health. 16,756.95 40.62 6.57 18.45 28.4 24.2 0.40
Glenmark Pharma. 15,498.19 40.15 6.14 23.94 12.7 11.7 0.39
Piramal Enterp. 10,037.23 0.00 0.95 23.66 0.8 2.1 0.07
Ipca Labs. 7,378.91 22.19 5.85 10.09 24.2 23.7 0.49
Torrent Pharma. 6,230.57 11.65 4.78 11.66 29.6 25.5 0.48
Biocon 5,708.00 19.90 2.59 12.20 12.6 13.6 0.08
Aurobindo Pharma 5,598.32 13.31 2.24 22.89 10.7 8.8 1.01
Strides Arcolab 5,198.17 35.44 3.79 16.20 5.1 5.7 0.97
Mylan Lab. 3,273.19 6.80 1.77 0.00 26.9 26.1 0.59
Alembic Pharma 2,470.29 15.69 5.37 5.60 39.5 27.7 1.07

Futures & Options Quote

 
Expiry Date
193.30 0.60  [0.3]%
Instrument: FUTSTK
Expiry Date: 30 May 2013
Open Price: 194.50
Average Price: 194.05
No. of Contracts Traded: 2,774,000
Open Interest: 10,818,000
Underlying: AUROPHARMA
Market Lot: 2000
Previous Close: 193.30
Day’s High | Low: 196.20 | 192.45
Turnover (Cr.): 53.83
Open Int. Change: 118,000.00 (1.1% )
View detailed F& O quotes >>

Key Information

Key Executives:

P V Ramprasad Reddy , Whole-time Director 

K Nithyananda Reddy , Vice Chairman 

M Sivakumaran , Whole-time Director 

M Madan Mohan Reddy , Whole-time Director 


Company Head Office / Quarters:
Plot No 2 Maitrivihar,
Behind Maithri Vanam Ameerpet,
Hyderabad,
Andhra Pradesh-500038
Phone : 91-40-66725000
Fax : 91-40-23741080/23746833
E-mail :
info@aurobindo.com
investorgrievances@aurobindo.co
Web : http://www.aurobindo.com
Registrars:
Karvy Computershare Pvt Ltd
Plot No 17-24
Vittal Rao Nagar
Madhapur
Hyderabad-500081

Fund Holding


Calendar

May-2013
M T W T F S S
13 14 15 16 17 18 19
IPO
listIssue Open : Onesource Techm.
Economic Events
list No economic event today
Results
list No result today